These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12048364)

  • 1. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy.
    Núñez M; Ríos P; Martín-Carbonero L; Pérez-Olmeda M; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2002 May; 30(1):65-8. PubMed ID: 12048364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes.
    Maida I; Babudieri S; Selva C; D'Offizi G; Fenu L; Solinas G; Narciso P; Mura MS; Núñez M
    AIDS Res Hum Retroviruses; 2006 Feb; 22(2):139-43. PubMed ID: 16478395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort.
    Torti C; Lapadula G; Puoti M; Casari S; Uccelli MC; Cristini G; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Caputo SL; Bonora S; Carosi G
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):180-5. PubMed ID: 16394850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy.
    Bower WA; Culver DH; Castor D; Wu Y; James VN; Zheng H; Hammer S; Kuhnert WL; Williams IT; Bell BP; Vlahov D; Dezzutti CS
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):293-7. PubMed ID: 16763522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?
    Rancinan C; Neau D; Savès M; Lawson-Ayayi S; Bonnet F; Mercié P; Dupon M; Couzigou P; Dabis F; Chêne G;
    AIDS; 2002 Jul; 16(10):1357-62. PubMed ID: 12131212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3.
    Seminari E; Tinelli C; Ravasi G; Ripamonti D; Ladisa N; Marino N; Sighinolfi L; Mondello P; Migliorino M; Carosi G; Maserati R;
    Curr HIV Res; 2010 Apr; 8(3):186-93. PubMed ID: 20163342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders?
    Gavazzi G; Bouchard O; Leclercq P; Morel-Baccard C; Bosseray A; Dutertre N; Micoud M; Morand P
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1021-3. PubMed ID: 10933615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
    Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
    J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
    Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype.
    Caudai C; Pianese M; Zacchini F; Toti M; Zazzi M; Valensin PE
    J Clin Virol; 2005 Feb; 32(2):151-5. PubMed ID: 15653418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy.
    Uberti-Foppa C; De Bona A; Morsica G; Galli L; Gallotta G; Boeri E; Lazzarin A
    J Acquir Immune Defic Syndr; 2003 Jun; 33(2):146-52. PubMed ID: 12794546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly active antiretroviral therapy-related hepatotoxicity in human immunodeficiency virus and hepatitis C virus co-infected patients with advanced liver fibrosis in Taiwan.
    Chou CC; Tsai HC; Wu KS; Sy CL; Chen JK; Chen YS; Lee SS
    J Microbiol Immunol Infect; 2016 Aug; 49(4):546-53. PubMed ID: 25440980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver enzymes elevation after HAART in HIV-HCV co-infection.
    Servin-Abad L; Molina E; Baracco G; Arosemena L; Regev A; Jeffers L; Schiff E
    J Viral Hepat; 2005 Jul; 12(4):429-34. PubMed ID: 15985015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection.
    Berger A; von Depka Prondzinski M; Doerr HW; Rabenau H; Weber B
    J Med Virol; 1996 Apr; 48(4):339-43. PubMed ID: 8699166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
    Ofotokun I; Smithson SE; Lu C; Easley KA; Lennox JL
    Am J Med Sci; 2007 Nov; 334(5):334-41. PubMed ID: 18004087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 28B rs12979860 (CT/TT) genotype is associated with milder hepatic damage in the natural evolution of HCV/HIV coinfection.
    de la Fuente C; Hinojosa C; Gilabert I; Jiménez Sousa MÁ; González JM; Ortiz de Lejarazu R; Loma A; Nieto C; Arnaiz R; Bermejo-Martin JF
    J Interferon Cytokine Res; 2013 Jan; 33(1):43-7. PubMed ID: 23030669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.